MAGRIT Trial

An ASCI (Antigen-Specific Cancer Immunotherapeutics) that specifically targets the MAGE-A3 antigen is being developed as a potential new treatment for a lung cancer sub-type: Non-Small Cell Lung Cancer (NSCLC). ASCI can work by educating our own immune system to fight cancer. Encouraging results observed in a group of lung cancer patients have led to the setting up of a large Phase III clinical study in lung cancer treatment, called MAGRIT (MAGE-A3 as Adjuvant, Non-Small Cell Lung Cancer Immunotherapy).

Objective of MAGRIT clinical study

The purpose of this study is to measure how well the MAGE-A3 ASCI works in preventing cancer from coming back when administered to patients with NSCLC and after removal of their tumor by surgery. It will also evaluate the potential side effects of the MAGE-A3 ASCI.

It will be measured by periodic exams (including X-rays or CT scans, blood tests and physical examinations) at the hospital where you receive the treatment.

What will the treatment consist of?

Over a period of 27 months, 13 injections will be made in the muscle of your upper arm. The first 5 injections will be given every 3 weeks, the next 8 every 3 months.

How long will the study last?

After the treatment, you will receive regular check-ups every 6 months up until 5 years after your first treatment, in order to continue checking that cancer has not returned. Finally, your progress will be checked annually by phone contact up until 10 years from the start of treatment.

Where will the study take place?

Approximately 400 hospitals all over the world – in Europe, Asia and America – will be involved in this study. You will receive your treatment and check-ups at the participating hospital you choose. To find the study hospital nearest to you, click here.